Michael Barbella, Managing Editor04.09.21
High-quality diabetic care management and easy access to healthcare facilities is expected to fuel the diabetes assays market in Australia, according to GlobalData.
Also driving market growth will be the necessity to screen and monitor diabetes patients, GlobalData asserts. The market declined in 2020 due to the COVID-19 pandemic but is expected to recover in 2021 with growth returning from 2022 onwards.
GlobalData's latest report, "Diabetes Assays (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)," reveals that glycated hemoglobin (HbA1c) POC assays and HbA1c laboratory assays accounted for more than 90 percent of the Australian diabetes assays market in 2020.
Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., and Abbott Laboratories are the leading players in Australia.
“HbA1c POC and laboratory assays are used for both diagnosis and monitoring of diabetic patients. High quality diabetic care management and easy access to healthcare facilities in Australia are expected to boost the diabetes assays market growth. Growing awareness about the importance of diagnosis, regular screening of high risk population and proper utilization of government schemes such as National Diabetes Services Scheme and Medicare Safety Nets Scheme to limit the out of pocket spending are expected to further contribute to the growth of diabetes assays market in Australia,” said Gundreddy Gopinadh, a Medical Devices analyst at GlobalData.
Also driving market growth will be the necessity to screen and monitor diabetes patients, GlobalData asserts. The market declined in 2020 due to the COVID-19 pandemic but is expected to recover in 2021 with growth returning from 2022 onwards.
GlobalData's latest report, "Diabetes Assays (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)," reveals that glycated hemoglobin (HbA1c) POC assays and HbA1c laboratory assays accounted for more than 90 percent of the Australian diabetes assays market in 2020.
Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., and Abbott Laboratories are the leading players in Australia.
“HbA1c POC and laboratory assays are used for both diagnosis and monitoring of diabetic patients. High quality diabetic care management and easy access to healthcare facilities in Australia are expected to boost the diabetes assays market growth. Growing awareness about the importance of diagnosis, regular screening of high risk population and proper utilization of government schemes such as National Diabetes Services Scheme and Medicare Safety Nets Scheme to limit the out of pocket spending are expected to further contribute to the growth of diabetes assays market in Australia,” said Gundreddy Gopinadh, a Medical Devices analyst at GlobalData.